『徳島大学 教育・研究者情報データベース (EDB)』---[学外] /
ID: Pass:

登録内容 (EID=258416)

EID=258416EID:258416, Map:0, LastModified:2013年5月28日(火) 17:11:59, Operator:[三木 ちひろ], Avail:TRUE, Censor:0, Owner:[近藤 和也], Read:継承, Write:継承, Delete:継承.
種別 (必須): 学術論文 (審査論文) [継承]
言語 (必須): 英語 [継承]
招待 (推奨):
審査 (推奨):
カテゴリ (推奨):
共著種別 (推奨):
学究種別 (推奨):
組織 (推奨):
著者 (必須): 1.山本 洋太
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
2. (英) Hiromichi Yamai (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
3.清家 純一
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
4.吉田 卓弘 ([徳島大学.病院.診療科.外科.食道・乳腺甲状腺外科])
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
5.武知 浩和
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
6.古北 由仁
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
7.梶浦 耕一郎
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
8. (英) Takuya Minato (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
9.坂東 良美 ([徳島大学.病院.中央診療施設等.病理部])
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
10.丹黒 章 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.外科系.胸部・内分泌・腫瘍外科学])
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
題名 (必須): (英) Prognosis of Esophageal Squamous Cell Carcinoma in Patients Positive for Human Epidermal Growth Factor Receptor Family Can Be Improved by Initial Chemotherapy with Docetaxel, Fluorouracil and Cisplatin  (日)    [継承]
副題 (任意):
要約 (任意): (英) The human epidermal growth factor receptor (HER) family, Ki-67 and p53 are important biomarkers for several malignancies. However, few studies have examined the role of these in prognosis and therapeutic sensitivity of esophageal squamous cell carcinoma (ESCC). The efficacy of triple-drug combination therapy with docetaxel, fluorouracil and cisplatin has recently been expected for ESCC. Subjects comprised 142 patients with ESCC who underwent operation (OP group, n = 54), neoadjuvant chemotherapy with docetaxel, fluorouracil, and cisplatin (DFP therapy) followed by operation (NAC group, n = 37) or initial systemic DFP therapy (CT group, n = 51) between January 2004 and December 2010. Immunohistochemical expressions of epidermal growth factor receptor (EGFR), HER2, HER3, Ki-67, and p53 were evaluated and compared with prognosis and sensitivity to DFP therapy. Positive correlations existed between EGFR, HER2, and HER3 expressions. In the OP group, EGFR was independently associated with postoperative recurrence in multivariate analysis (P = .036). In the NAC group, EGFR correlated with pathological response to DFP therapy (P = .004). In the CT group, EGFR, HER2, and HER3 correlated with clinical response to DFP therapy and EGFR was independently associated with favorable prognosis in multivariate analysis (P = .022). EGFR represents a predictor of postoperative recurrence and sensitivity to triple-drug combination therapy including a taxane. EGFR-positive patients may show improved prognosis with taxane combination chemotherapy and molecular targeted therapy for HER family members.  (日)    [継承]
キーワード (推奨): 1. (英) Aged (日) (読) [継承]
2. (英) Antineoplastic Combined Chemotherapy Protocols (日) (読) [継承]
3. (英) Carcinoma, Squamous Cell (日) (読) [継承]
4. (英) Cisplatin (日) (読) [継承]
5. (英) Disease-Free Survival (日) (読) [継承]
6. (英) Esophageal Neoplasms (日) (読) [継承]
7. (英) Esophagectomy (日) (読) [継承]
8. (英) Female (日) (読) [継承]
9. (英) Fluorouracil (日) (読) [継承]
10. (英) Humans (日) (読) [継承]
11.免疫組織化学 (immunohistochemistry) [継承]
12. (英) Ki-67 Antigen (日) (読) [継承]
13. (英) Male (日) (読) [継承]
14. (英) Middle Aged (日) (読) [継承]
15. (英) Neoadjuvant Therapy (日) (読) [継承]
16. (英) Prognosis (日) (読) [継承]
17. (英) Receptor, Epidermal Growth Factor (日) (読) [継承]
18. (英) Receptor, erbB-2 (日) (読) [継承]
19. (英) Receptor, erbB-3 (日) (読) [継承]
20. (英) Survival Rate (日) (読) [継承]
21. (英) Taxoids (日) (読) [継承]
22. (英) Tumor Markers, Biological (日) (読) [継承]
23. (英) Tumor Suppressor Protein p53 (日) (読) [継承]
発行所 (推奨):
誌名 (必須): Annals of Surgical Oncology (Society of Surgical Oncology (U.S.))
(pISSN: 1068-9265, eISSN: 1534-4681)

ISSN (任意): 1534-4681
ISSN: 1068-9265 (pISSN: 1068-9265, eISSN: 1534-4681)
Title: Annals of surgical oncology
Title(ISO): Ann. Surg. Oncol.
Supplier: Springer Online Journal Archive
Publisher: Springer New York
 (NLM Catalog  (Scopus  (CrossRef (Scopus information is found. [need login])
[継承]
[継承]
(必須): 19 [継承]
(必須): 3 [継承]
(必須): 757 765 [継承]
都市 (任意):
年月日 (必須): 西暦 2012年 3月 初日 (平成 24年 3月 初日) [継承]
URL (任意):
DOI (任意): 10.1245/s10434-011-2071-y    (→Scopusで検索) [継承]
PMID (任意): 21947696    (→Scopusで検索) [継承]
NAID (任意):
WOS (任意): 000300313800010 [継承]
Scopus (任意):
評価値 (任意):
被引用数 (任意):
指導教員 (推奨):
備考 (任意): 1.(英) Article.ELocationID: 10.1245/s10434-011-2071-y  (日)    [継承]
2.(英) Article.Affiliation: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, Japan. youtayotayota@yahoo.co.jp  (日)    [継承]
3.(英) Article.PublicationTypeList.PublicationType: Journal Article  (日)    [継承]

標準的な表示

和文冊子 ● Yota Yamamoto, Yamai Hiromichi, Jun-ichi Seike, Takahiro Yoshida, Hirokazu Takechi, Yoshihito Furukita, Koichiro Kajiura, Minato Takuya, Yoshimi Bando and Akira Tangoku : Prognosis of Esophageal Squamous Cell Carcinoma in Patients Positive for Human Epidermal Growth Factor Receptor Family Can Be Improved by Initial Chemotherapy with Docetaxel, Fluorouracil and Cisplatin, Annals of Surgical Oncology, Vol.19, No.3, 757-765, 2012.
欧文冊子 ● Yota Yamamoto, Yamai Hiromichi, Jun-ichi Seike, Takahiro Yoshida, Hirokazu Takechi, Yoshihito Furukita, Koichiro Kajiura, Minato Takuya, Yoshimi Bando and Akira Tangoku : Prognosis of Esophageal Squamous Cell Carcinoma in Patients Positive for Human Epidermal Growth Factor Receptor Family Can Be Improved by Initial Chemotherapy with Docetaxel, Fluorouracil and Cisplatin, Annals of Surgical Oncology, Vol.19, No.3, 757-765, 2012.

関連情報

Number of session users = 0, LA = 1.09, Max(EID) = 362780, Max(EOID) = 970360.